| Date | Title | Description |
| 22.06.2026 | Украинская «Биофарма» инвестирует около $500 млн в заводы в Украине и Румынии | Украинская биотехнологическая компания «Биофарма» Константина Ефименко продолжает расширять производственные мощности и международное присутствие. Компания готовится запустить новый завод в Ужгороде уже в сентябре 2026 года, строит крупное ... |
| 31.03.2026 | Enzymatica and STADA sign partnership agreement for Germany and Austria | Enzymatica and STADA sign partnership agreement for Germany and Austria
Tue, Mar 31, 2026 14:00 CET Report this content
Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica’s ColdZyme® te... |
| 22.09.2025 | Europe’s IPO uptick sparks hopes of a much needed rebound | Companies across the fintech, defense, software and energy sectors have either recently floated or are rumored to be eyeing an IPO in Europe.
It follows a prolonged period of sluggishness for public listings in Europe, which has been laggin... |
| 01.09.2025 | CapVest из Лондона покупает 70% фармпроизводителя Stada у инвестфондов Bain и Cinven за €10 млрд | Лондонская инвестиционная компания приобретает контрольный пакет у нынешних владельцев Stada — фондов частных инвестиций Bain Capital и Cinven, которые сохранят миноритарную долю после завершения сделки, говорится в заявлении в понедельник.... |
| 21.03.2025 | The New Frontier: X and CVC Capital’s Bold Moves in a Shifting Landscape | In the fast-paced world of finance and technology, two stories stand out. One is the evolution of X, the social media platform formerly known as Twitter. The other is CVC Capital Partners, a private equity firm eyeing opportunities in the U... |
| 20.03.2025 | Buyout Firm CVC Eyes US Private Credit in Expansion Drive | CVC Capital Partners Plc has identified private credit in the US as an area for potential acquisitions, according to Chief Executive Officer Rob Lucas.
There are “huge opportunities” for CVC in private wealth and insurance business, Lucas s... |
| 12.12.2024 | Stada привлечет инвестиции на сумму более €1,5 млрд | Производитель лекарственных препаратов Stada Arzneimittel AG планирует первичное размещение акций. По словам источников, это может помочь привлечь финансирование в размере около €1,5 млрд, сообщает Bloomberg. Размер сделки может увеличиться... |
| 05.12.2024 | Kyan Health: $16.7 Million Secured For Upgrading Workplace Wellness | Kyan Health announced it raised $16.7 million in funding. The company combines AI-powered preventive care with organizational insights that help companies treat employee well-being as a strategic and measurable investment rather than a box-... |
| 28.11.2024 | Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List | SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 27.11.2024 | Kyan Health raises USD $16.7m for AI-driven care | Workplace mental health platform Kyan Health has raised USD $16.7 million to enhance AI-driven preventative care for businesses.
Based in Zurich, Kyan Health aims to shift the approach towards employee well-being from reactive support to st... |
| 26.11.2024 | USD16.7 million to expand Kyan Health’s workplace wellness platform globally |
One in five workdays is lost to poor mental health, yet companies continue pouring billions into wellness programs that fail to move the needle. Today, Kyan Health announces $16.7M in funding to transform this broken model, combining AI-po... |
| 26.11.2024 | Zurich-based Kyan Health raises €15.8 million to transform workplace wellness with AI-powered preventative care | Swiss startup Kyan Health has announced €15.8 million in funding to advance its AI-driven platform for employee mental health and wellbeing.
The funding combines a previously unannounced €3.7 million seed round led by Amplo VC with a €12 mi... |
| 16.09.2024 | The Future of Finance: Partnerships and Leadership in a Changing Landscape | In the fast-paced world of finance, partnerships are the lifeblood of innovation. Companies are not just looking to survive; they aim to thrive. Recent developments from Genpact and STADA, as well as PrimeRevenue, illustrate this trend vivi... |
| 12.09.2024 | Genpact and STADA Renew Multi-Year Partnership to Enhance Finance Operations | Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages
NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions fi... |
| 14.08.2024 | Calliditas and Asahi Kasei: A Strategic Dance in the Biopharma Arena | In the fast-paced world of biopharmaceuticals, every move counts. Calliditas Therapeutics AB, a Swedish biopharma company, recently unveiled its interim report for the first half of 2024. The numbers tell a story of growth, challenges, and ... |
| 13.08.2024 | Calliditas Interim Report January to June 2024 | Calliditas Interim Report January to June 2024
Tue, Aug 13, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX):
April to June 2024 (compared to April to June 2023) Net sales amounted to SEK... |
| 27.07.2024 | Calliditas Therapeutics: A Beacon of Hope in Rare Disease Treatment | In the ever-evolving landscape of biopharmaceuticals, Calliditas Therapeutics is making waves. The company recently announced significant advancements in two of its key treatments, setanaxib and Kinpeygo, which target rare diseases with sub... |
| 26.07.2024 | Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy | Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Fri, Jul 26, 2024 17:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: C... |
| 18.07.2024 | Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million | Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million
Thu, Jul 18, 2024 07:45 CET Report this content
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATE... |
| 30.05.2024 | Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy | Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Thu, May 30, 2024 20:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockho... |
| 23.05.2024 | Calliditas Q1 report, January – March 2024 | Calliditas Q1 report, January – March 2024
Thu, May 23, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX):
Target market expansion following full approval in the US
JANUARY – MARCH 2024 (COMPARED TO JAN... |
| 18.04.2024 | Digital Health-Startup Kyan Health auf Wachstumskurs |
Knapp 60 Prozent aller befragten Personen aus über 30 Ländern gaben letztes Jahr an, dass sie in den vergangenen 12 Monaten mindestens einmal wegen zu viel Stress der Arbeit fernblieben. Das zeigen Umfrageergebnisse des Forschungsinstituts... |
| 03.04.2023 | STADA and Xbrane launch ranibizumab to support patient access in Europe | Peter Goldschmidt, STADA CEO
• Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane
This European-made biosimilar, developed through STADA’s strategic partnership with Xbrane, will he... |
| 06.03.2023 | STADA sustains strong momentum with double-digit sales and profit growth in 2022 | Peter Goldschmidt, STADA CEO
• STADA sustains growth trajectory in 2022 with growth of 11% in sales and 17 % in EBITDA
STADA was able in 2022 to sustain its strong growth journey of recent years. I am confident that STADA has the right pipe... |
| 09.02.2023 | EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) | Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA)
The EMA’s acceptance for filing marks a key milestone in making an additional treatment op... |
| 11.01.2023 | Adalvo and STADA extend their strategic partnership | STADA has extended its strategic partnership with Adalvo
Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes
Working closely as a trusted partner with Adalvo ... |
| 02.01.2023 | STADA appoints Boris Döbler as Chief Financial Officer | Boris Döbler, STADA CFO
STADA appoints Döbler CFO
• STADA’s VP Corporate Financial Planning & Analysis and former European Markets CFO Boris Döbler appointed as STADA’s Chief Financial Officer
I am convinced that Boris’ expertise, dedic... |
| 20.12.2022 | STADA ranks among top 10% of pharma firms on sustainability | STADA ESG Summary
Independent Sustainalytics ESG Risk Rating puts STADA among top 10% of pharma firms globally
STADA’s commitment to sustainable development stems from the Group’s purpose of Caring for People’s Health as a Trusted Partner.”... |
| 28.11.2022 | STADA Starts Work on >EUR50m Facility to Strengthen European Medicines Supply | STADA CTO Miguel Pagan presents details of the planned facility
STADA breaks ground on EUR50 mn+ investment in medicines supply-chain hub in Romania. Site expected to supply 100 million packs per year, creating 375 jobs
Through this major i... |
| 20.09.2022 | STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease | Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A nephropathy (IgAN)
Making this medicine available to primary IgAN patients in Europe brings for the first time a therapeuti... |
| 11.07.2022 | STADA Health Report 2022: Europe experiencing worsening health conditions | STADA Health Report 2022 reveals European healthcare trends
STADA has published its STADA Health Report 2022
STADA Peter Goldschmidt launches the STADA Health Report 2022 (Source: Johannes Jost for Hubert Burda Media / STADA))
STADA Health ... |
| 18.08.2021 | DGAP-AFR : STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] | DGAP Preliminary announcement financial reports: STADA Arzneimittel AG / Preliminary announcement on the disclosure of financial statements STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to... |
| 12.07.2021 | Enzymatica and STADA extend agreement on ViruProtect to Vietnam | Enzymatica and STADA extend agreement on ViruProtect to Vietnam Mon, Jul 12, 2021 15:00 CET
Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (ColdZyme®) in Vietnam. The agreement builds on the two companies’... |
| 15.03.2017 | PE consortia make binding $5b bid to takeover drugmaker Stada | Premium
The two private equity consortia vying for Stada have made binding takeover offers each worth 4.7 billion euros ($5.0 billion) including debt, paving the way for a deeper look into the German generic drugmaker‘s books, several peopl... |
